Informatie:
Fout:
ID
13342
Beschrijving
PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.; ODM derived from: https://clinicaltrials.gov/show/NCT00180973
Link
https://clinicaltrials.gov/show/NCT00180973
Trefwoorden
Versies (1)
- 07-02-16 07-02-16 -
Geüploaded op
7 februari 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT NCT00180973
Eligibility LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT NCT00180973
- StudyEvent: Eligibility
Similar models
Eligibility LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT NCT00180973
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Gender
Item
of either sex
boolean
C0079399 (UMLS CUI [1])
Age
Item
aged 15 to 70 years
boolean
C0001779 (UMLS CUI [1])
ID.3
Item
never previously treated with radiotherapy, chemotherapy or surgery for malignant disease (except neck adenectomy/diagnosis)
boolean
C0087111 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0038894 (UMLS CUI [4])
C1522449 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0038894 (UMLS CUI [4])
who performance
Item
with awho performance status * 2.
boolean
C1298650 (UMLS CUI [1])
follow-up
Item
amenable to regular follow-up
boolean
C1321605 (UMLS CUI [1])
capable of receiving therapy
Item
capable of receiving chemotherapy and radiotherapy : in particular, with no contraindications to the use of anthracyclines, bleomycin or cisplatinum.
boolean
C1321605 (UMLS CUI [1])
informed consent
Item
with informed consent at entry time, in writing or witnessed oral informed consent, in accordance with local legislation requirements.
boolean
C0021430 (UMLS CUI [1])
Laboratory results
Item
neutrophil count * 2000 /mm3 platelet count * 150,000 /mm3 hemoglobin * 10 g / dl
boolean
C0200633 (UMLS CUI [1])
C0005821 (UMLS CUI [2])
C0019046 (UMLS CUI [3])
C0005821 (UMLS CUI [2])
C0019046 (UMLS CUI [3])
histology
Item
histologic types other than type ii - iii of the who classification
boolean
C0449574 (UMLS CUI [1])
Tumor stage
Item
t1 - t2 n0 - n1 or patients with metastatic
boolean
C1300072 (UMLS CUI [1])
Age
Item
aged < 15 or > 70.
boolean
C0001779 (UMLS CUI [1])
contraindication chemotherapy, myocardial infarcion, heart diseases
Item
patients in whom chemotherapy is contraindicated: history of myocardial infarction over the last 6 months before inclusion, or clinically present cardiac pathology.
boolean
C1301624 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0027051 (UMLS CUI [2])
C0018799 (UMLS CUI [3])
C0392920 (UMLS CUI [1,2])
C0027051 (UMLS CUI [2])
C0018799 (UMLS CUI [3])
who performance
Item
who performance status >2
boolean
C1298650 (UMLS CUI [1])
prior malignancies
Item
history of prior malignancies (other than non melanoma skin cancer or excised cervical carcinoma in situ).
boolean
C0006826 (UMLS CUI [1])
uncontrolled infection
Item
uncontrolled infection,
boolean
C0009488 (UMLS CUI [1])
refusing participation
Item
patients refusing participation.
boolean
C1321605 (UMLS CUI [1])
unlikely to comply with a long term follow-up
Item
patients who, for social, familial or geographic reasons are unlikely to comply with a long term follow-up.
boolean
C1321605 (UMLS CUI [1])